Merck & Co., Inc. (NYSE:MRK) Shares Bought by SignalPoint Asset Management LLC

SignalPoint Asset Management LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 6.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,911 shares of the company’s stock after acquiring an additional 436 shares during the period. SignalPoint Asset Management LLC’s holdings in Merck & Co., Inc. were worth $567,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Qube Research & Technologies Ltd bought a new position in Merck & Co., Inc. during the 4th quarter valued at $14,875,000. Assenagon Asset Management S.A. boosted its stake in Merck & Co., Inc. by 8.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 49,999 shares of the company’s stock valued at $3,832,000 after acquiring an additional 3,741 shares during the last quarter. RFG Advisory LLC boosted its stake in Merck & Co., Inc. by 2.7% during the 4th quarter. RFG Advisory LLC now owns 20,951 shares of the company’s stock valued at $1,606,000 after acquiring an additional 547 shares during the last quarter. Castle Rock Wealth Management LLC boosted its stake in Merck & Co., Inc. by 5.6% during the 4th quarter. Castle Rock Wealth Management LLC now owns 2,874 shares of the company’s stock valued at $230,000 after acquiring an additional 153 shares during the last quarter. Finally, Valmark Advisers Inc. boosted its stake in Merck & Co., Inc. by 5.2% during the 4th quarter. Valmark Advisers Inc. now owns 20,590 shares of the company’s stock valued at $1,578,000 after acquiring an additional 1,012 shares during the last quarter. 72.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on MRK. UBS Group increased their target price on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a report on Monday, July 18th. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Barclays increased their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. Finally, Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a report on Friday, July 29th. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $97.44.

Merck & Co., Inc. Stock Up 0.7 %

Shares of MRK stock traded up $0.59 during trading on Friday, hitting $87.41. 8,801,196 shares of the company were exchanged, compared to its average volume of 8,488,001. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.14 and a current ratio of 1.40. The firm has a market capitalization of $221.04 billion, a price-to-earnings ratio of 13.39, a P/E/G ratio of 1.17 and a beta of 0.32. The business’s 50-day simple moving average is $90.27 and its 200 day simple moving average is $85.38. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. The firm had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.31 earnings per share. As a group, analysts forecast that Merck & Co., Inc. will post 7.31 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be given a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is 42.27%.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.